The benefits of G8 and VES-13 geriatric screening tools for older patients with advanced lung cancer

Abstract

Cancer is a disease of ageing. There is scarce evidence to guide proper cancer treatment decisions for this population because older patients, especially those with age-related comorbidities, are under-represented in clinical trials [1]. During the past decades, there have been major breakthroughs in non-small cell lung cancer treatment. Up to half of the Asian patients with adenocarcinoma harbor epidermal growth factor receptor (EGFR) mutations – the predictive biomarker of EGFR tyrosine kinase inhibitors (EGFR TKIs) [2].